Royalty Report: Drugs, Pharmaceuticals, Therapeutic – Collection: 5378

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 9

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Therapeutic
  • Disease
  • Delivery
  • Drug Discovery
  • Diabetes Treatment
  • obesity

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 5378

License Grant
The Company grants an exclusive, world-wide license, with a right of sub-license, in the Field of Use to all the Patent Rights, subject to the terms of this Agreement, to use and sell Products; whose manufacture, sale or use is claimed in the Patent Rights relates to treating male sexual dysfunction and female sexual dysfunction in humans and animals.
License Property
U.S. Patent Application 08/825,121 / U.S. Patent 5,952,006 Drug preparations for treating impotency.
Field of Use
Field of Use for the treatment of male sexual dysfunction and female sexual dysfunction in humans and animals including
(a)   Female Dryness / Lubrication
(b)   Erectile Dysfunction
(c)   Painful Sex (e.g. vaginismus, etc.)
(d)   Such other areas within the Field of Use which may be identified from time
      to time by Licensor or Licensee, including but not limited to
1.    Premature Ejaculation
2.    Retarded Ejaculation
3.    Stimulation
4.    Orgasm
5.    Sexual Performance Anxiety
6.    Sexual Arousal
7.    Semen Production
8.    Drug induced sexual disorders

IPSCIO Record ID: 367114

License Grant
Licensor hereby grants Licensee the exclusive right and license to practice the Licensor's Patents and the Licensor Know-How to develop, have developed, make, have made, use, import, export, offer for sale, sell and have sold Licensed Products for the Indications anywhere in the world as well as further license the Product and/or the Licensed Products for the Indications for one or more of the Indications provided such licensing shall not affect the right of Autotelic under this agreement.

Licensor will out-license its product comprising of the intra-nasal drug and delivery system related to, but not limited to, nasal apomorphine (the Product) to Licensee. Licensee will license AL-101, intranasal apomorphine, from Licensor.

License Property
AL-101, intranasal apomorphine, has a favorable safety and efficacy profile and is phase 3 ready with six clinical trials completed and over 200 patients (2,200 doses) treated. Apomorphine is a direct-acting dopamine agonist with strong D1 and D2 dopamine receptor–stimulating properties that is administered by a parenteral route (intravenously, rectally, subcutaneously, sublingually, or intranasally). It has similar efficacy to levodopa with a substantially more rapid time to onset.

PATENTS
Application No. 63235101, Intranasal Apomorphine – Methods of Use

Application No. 63243175, Fast Acting Treatment of Parkinson with Rapid Delivery of Drug to Brainstem

Application No. 63243177, Combination Therapy for Erectile Dysfunction

INDICATIONS
Parkinson’s Disease
Erectile dysfunction
Female sexual dysfunction (also called hypoactive sexual desire disorder)

“Indications” shall mean Parkinson’s Disease (PD), erectile dysfunction (ED), female sexual dysfunction (FSD – also called hypoactive sexual desire disorder (HSDD)) or any other indications related to the Product that are or may be identified in the future.

Field of Use
Field of use is for the treatment of Parkinson Disease (PD) and Erectile Dysfunction (ED), especially phosphodiesterase 5 (PDE5) non-responders. AL-101 will also be developed as a new drug against Female Sexual Dysfunction (FSD), including Hypoactive Sexual Desire Disorder (HSDD).

PDE5 is an enzyme in the walls of blood vessels. It affects blood flow and how cells signal within the body. PDE5 inhibitors block the PDE5 enzyme to prevent it from working. This inhibition relaxes the blood vessels and increases blood flow.

Hypoactive Sexual Desire Disorder — also called HSDD — is when you're not interested in sex (have no sex drive or a low sex drive), and it bothers you. It's one of the most common sexual problems that people have.

IPSCIO Record ID: 4898

License Grant
The Company entered into a royalty agreement with the Licensor, an individual, for the intellectual rights to patent, develop, manufacture, and market the LLPGE-1 for the treatment of male erectile dysfunction, impotency and sexual enhancement.
License Property
U.S. Patent 573408 PGE-1 containing lyophilized liposomes for use in the treatment of erectile dysfunction.
Field of Use
The field of use relates to the medical industry.  The Licensee is a development stage biopharmaceutical company whose corporate objective is to utilize medically researched and developed drug substances for sexual dysfunction, determine the ability of these substances to be delivered effectively and determine the potential market for such products.

IPSCIO Record ID: 27826

License Grant
Pursuant to the Development Agreement, Licensor has granted Licensee certain intellectual property licenses related to, among other things, a pharmaceutical composition known as Dapoxetine.  As permitted by the Development Agreement, Licensee has sublicensed to Alza, Corporation (Alza) certain rights to develop and market Dapoxetine in exchange for which Licensee is entitled to receive certain milestone, royalty and other payments from Alza.  The parties now desire to, among other things, (i) terminate the Development Agreement.
License Property
“Compounds” means those compounds other than Dapoxetine covered by a Valid Claim within the scope of the Licensed Patents.

Dapoxetine is acompound developed specially for the treatment of premature ejaculation (PE) in men 18–64 years old. Dapoxetine works by inhibiting the serotonin transporter, increasing serotonin's action at the post synaptic cleft, and as a consequence promoting ejaculatory delay. As a member of the selective serotonin reuptake inhibitor (SSRI) family, dapoxetine was initially created as an antidepressant.

Field of Use
Field shall mean all therapeutic indications for use in humans (i.e. specifically excluding use in animals) within the urogenital area, including primary urinary incontinence, urge, stress and mixed incontinence, urinary urgency, interstitial cystitis, neurogenic bladder, bladder sphincter dyssynergia and irritative symptoms of benign prostate hypertrophy, hypoactive sexual desire, hyperactive sexual desire, impotence, retarded ejaculation, premature ejaculation, delayed
orgasm and anorgasmia.

IPSCIO Record ID: 305270

License Grant
Licensor granted to Canadian Licensee an exclusive sublicense in Canada for, among other things, the development and commercialization of Stendra® .
License Property
Stendra® is an FDA approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (“ED”). As a distinct molecule with high in-vitro affinity and selectivity for penile tissue (clinical significance of this in-vitro selectivity profile is unknown), Stendra® offers the erectile dysfunction therapeutic landscape a valuable addition as an oral ED therapy that may be taken as early as approximately 15 minutes prior to sexual engagement, with or without food when using the 100mg or 200mg dosing (does not apply to 50mg dosing).
Field of Use
The Field of Use is for the treatment of male erectile dysfunction.  Erectile Dysfunction is the inability to attain an erection when stimulated and the ability to maintain the erection to completion.

IPSCIO Record ID: 263945

License Grant
Licensor grants to the Licensee, of Sweden, a perpetual, exclusive, subject to a retained right thereto for the sole purpose of Licensor carrying out its obligations under the Research Collaboration, right and license in the Territory, with the right to grant sublicenses, under Licensors right, title and interest in and to the Compounds, the Licensed Products, the Licensed Patents, the Licensed Know-How and the
Licensed Improvements to use and otherwise Exploit the Compounds, the Licensed Products, the Licensed Patents, the Licensed Know-How and the Licensed Improvements for use within the Licensed Field.
License Property
The collaboration is based on Licensors melanocortin receptor Obesity program and includes access to compound libraries, core technologies and expertise in melanocortin receptor drug discovery and development.

Licensor is engaged in research regarding modulation of the activity of the MC4 receptor, including regulation of appetite for treatment of obesity, diabetes and related metabolic syndrome.

The licensed know-how is for Information relating to Compounds, including without limitation cell binding, functional and efficacy Information, including both in vitro and in vivo data, to the extent not disclosed in the Licensed Patents;  Information relating to development plans and proposed activities. including but not limited to proposed work and activities with respect to chemotypes, modification of existing chemotypes, synthetic methods, formulations and routes of administration; and,  Information relating to other signal transduction pathways, such as activation of MAPkinase and regulation of levels of intracellular calcium, linked to activation of MC4 receptors, including exploration of correlations to the mechanism of action of Compounds.

60/712.283 Compounds and Methods for Treating Obesity

60/712.282 Methods for Selection of Melanocortin Receptor-Specific Agents for Treatment of Obesity

Field of Use
The Licensed Field means the palliative, prophylactic or therapeutic treatment of mammalian, including human, obesity, diabetes and related metabolic syndrome by use of a Compound, other than such Compound mentioned under, which binds to the melanocortin-4 receptor or the melanocortin-3 receptor; or a Compound which binds to the melanocortin-4 receptor and is effective for palliative, prophylactic or therapeutic treatment of any mammalian, including human, disease, syndrome or condition as a result of such binding to the melanocortin-4 receptor, but specifically excluding from either of the compounds which are functionally antagonists at either or both the melanocortin-4 receptor and the melanocortin-3 receptor as determined by an adenylyl cyclase assay system and which at clinical relevant doses, in either animal models or humans, result over a clinically relevant period in an increase in body weight such that the specifically excluded compounds may be useful for treatment of cachexia and related indications, provided. however, that any such compound otherwise excluded shall if useful for treatment of obesity, diabetes or related metabolic syndrome be included in the Licensed Field; and Compounds used or useful solely for the SD Field.

SD Field means the palliative, prophylactic or therapeutic treatment of mammalian, including human, sexual dysfunction, including erectile dysfunction and all related subindications, such as organic, psychogenic or iatrogenic inability to achieve or maintain an erection, ejaculatory failure, premature ejaculation, retrograde ejaculation. inability to achieve an orgasm. and the like. and female sexual dysfunction and all related subindications, such as organic, psychogenic or iatrogenic persistent or recurrent failure to attain or maintain the lubrication-swelling response of sexual excitement until completion of sexual activitv, including inhibited orgasm, dvspareunia, hypoactive sexual desire disorder, sexual anhedonia, sexual arousal disorder, vagjnismus, and the like.

IPSCIO Record ID: 7215

License Grant
Licensor hereby grants a Korean  pharmaceutical company an exclusive royalty-bearing license, with the right to sublicense directly or through multiple tiers under the Licensor Technology, to research, Develop, Finish, use, have used, sell, have sold, offer for sale, have offered for sale, distribute, have distributed, import, have imported, and otherwise Commercialize the Products in the Field in the Territory.  For clarity, the foregoing licenses exclude the right to Manufacture or have Manufactured the Product, except for the right to Finish the Product.
License Property
The Licensee has made or will make certain specified milestone payments to the Licensor upon the signing of the Agreement, a specified period of time following approval of ZertaneTM for sale in South Korea, a specified period of time following approval of a combination drug for sale in South Korea and specified periods of time following the end of the first calendar quarter where cumulative net sales of products including ZertaneTM (including combination drugs) in South Korea exceed specified thresholds.
Field of Use
The Agreement provides the Licensee with exclusive rights to market ZertaneTM in South Korea for the treatment of premature ejaculation and for a combination drug, utilizing ZertaneTM and another erectile dysfunction drug (PDE5 inhibitors and others), to simultaneously treat premature ejaculation and erectile dysfunction.

IPSCIO Record ID: 26872

License Grant
Licensee (English company) entered into an exclusive license to utilize limited confidential technical information in licensor's (English company) possession that will assist licensee in its efforts to enter into pharmaceutical industry and further its efforts to develop products to treat lifestyle ailments (i.e. lifestyle drugs from sexual dysfunction to hair loss).

IPSCIO Record ID: 383748

License Grant
Company granted to Licensee an exclusive sublicense in Canada for, among other things, the development and commercialization of Stendra® avanafil.
License Property
Stendra® is a PDE-5 inhibitor that offers the ED therapeutic landscape a valuable addition as an oral ED therapy that may be taken as early as approximately 15 minutes prior to sexual engagement, with or without food when using the 100mg or 200mg dosing (does not apply to 50mg dosing).
Field of Use
Field of use is for the treatment of male erectile dysfunction (ED).
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.